HSBC Downgrades Pfizer to Hold, Lowers Price Target to $28

Benzinga Newsdesk www.benzinga.com Negative 93.4%

Neg 93.4% Neu 0% Pos 0%

HSBC analyst Rajesh Kumar downgrades Pfizer (NYSE:PFE) from Buy to Hold and lowers the price target from $32 to $28.

Comments

No comments yet. Be the first!